Skip to main content

Advertisement

Table 2 Corresponding IC50 values for each drug system at 24, 48 and 72 h incubation with cells

From: Fabrication of 6-gingerol, doxorubicin and alginate hydroxyapatite into a bio-compatible formulation: enhanced anti-proliferative effect on breast and liver cancer cells

Drug system IC50 on MCF-7 cells (µg/mL) IC50 on HEpG2 cells (µg/mL)
24 h 48 h 72 h 24 h 48 h 72 h
m-HAP Inactive Inactive Inactive Inactive Inactive Inactive
6-Gingerol 150.5 ± 10.6 102.4 ± 2.9 67.4 ± 6.9 118.9 ± 8.2 115.0 ± 7.9 32.1 ± 7.4
6-Gin-m-HAP 2.25 ± 0.73 1.38 ± 0.30 0.81 ± 0.17 44.9 ± 7.5 24.4 ± 7.8 3.43 ± 2.60
Doxorubicin 2.96 ± 0.96 3.03 ± 0.96 1.09 ± 0.46 53.0 ± 0.2 14.9 ± 4.1 1.14 ± 0.31
Dox-m-HAP 0.53 ± 0.15 0.43 ± 0.15 0.16 ± 0.05 7.69 ± 1.73 7.28 ± 2.19 0.58 ± 0.24
6-Gin + Dox-m-HAP 0.58 ± 0.07 0.53 ± 0.12 0.45 ± 0.09 0.55 ± 0.19 0.47 ± 0.05 0.19 ± 0.06